^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) + Sulanda (surufatinib) (VEGFR inhibitor, FGFR1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract CT142: A phase I trial of surufatinib plus toripalimab in patients with advanced solid tumor
Published date:
04/27/2020
Excerpt:
Most patients with negative or low PD-L1 expression achieved PR or CR.
DOI:
10.1158/1538-7445.AM2020-CT142
Trial ID:
